Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects

ConclusionThe favorable safety and tolerability and predictable pharmacokinetic profile of rhNGF in healthy Chinese subjects support its continuing clinical development for the treatment of nerve injury and neurodegenerative diseases. The AEs and immunogenicity of rhNGF will continue to be monitored in future clinical trials.Trial RegistrationThis study was registered with Chinadrugtrials.org.cn (ChiCTR2100042094) on January 13th, 2021.
Source: CNS Drugs - Category: Neurology Source Type: research